Read by QxMD icon Read

Royal marsden

Fernando Carceller, Francisco J Bautista, Irene Jiménez, Raquel Hladun-Álvaro, Cécile Giraud, Luca Bergamaschi, Madhumita Dandapani, Isabelle Aerts, François Doz, Didier Frappaz, Michela Casanova, Bruce Morland, Darren R Hargrave, Lynley V Marshall, Gilles Vassal, Andrew D J Pearson, Birgit Geoerger, Lucas Moreno
OBJECTIVES: Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise individual benefit, whilst ensuring adequate assessment of key study end-points. We assessed prognostic factors of survival in paediatric phase I trials, including two predictive scores validated in adult oncology: the Royal Marsden Hospital (RMH) and the MD Anderson Cancer Center (MDACC) scores. METHODS: Data of patients with solid tumours aged <18 years at enrolment in their first dose-finding trial between 2000 and 2014 at eight centres of the Innovative Therapies for Children with Cancer European consortium were collected...
November 2016: European Journal of Cancer
Jemma Bhoday, Fraser Smith, Muhammed R Siddiqui, Svetlana Balyasnikova, Robert I Swift, Rodrigo Perez, Angelita Habr-Gama, Gina Brown
BACKGROUND: Pathological complete response after chemoradiotherapy for rectal cancer occurs in 10% to 30% of patients. The best method to identify such patients remains unclear. Clinical assessment of residual mucosal abnormality is considered the most accurate method. In our institution, magnetic resonance tumor regression grade is performed as routine to assess response. OBJECTIVE: The purpose of this study was to compare the sensitivity of magnetic tumor regression grade against residual mucosal abnormality in detecting patients with a pathological complete response...
October 2016: Diseases of the Colon and Rectum
Hideaki Bando, Larry Rubinstein, Pamela Harris, Takayuki Yoshino, Toshihiko Doi, Atsushi Ohtsu, John Welch, Naoko Takebe
BACKGROUND: In phase 1 trials, an important entry criterion is life expectancy predicted to be more than 90 days, which is generally difficult to predict. The Royal Marsden Hospital (RMH) prognostic score that is determined by lactate dehydrogenase level, albumin level, and number of metastatic sites of disease was developed to help project patient outcomes. There have been no systematic analyses to evaluate the utility of the RMH prognostic score for esophagogastric cancer patients...
August 10, 2016: Gastric Cancer
H G Smith, N Memos, J M Thomas, M J F Smith, D C Strauss, A J Hayes
BACKGROUND: Extremity soft-tissue sarcomas comprise a range of distinct histological subtypes. This study aimed to characterize the patterns of disease relapse in patients undergoing resection of primary extremity soft-tissue sarcoma. METHODS: All patients who had resection of primary extremity soft-tissue sarcoma at the Royal Marsden Hospital between January 2004 and January 2014 were identified from an institutional database. RESULTS: In the period examined, 556 patients underwent resection...
October 2016: British Journal of Surgery
James Alexander, Louise Gildea, Julia Balog, Abigail Speller, James McKenzie, Laura Muirhead, Alasdair Scott, Christos Kontovounisios, Shanawaz Rasheed, Julian Teare, Jonathan Hoare, Kirill Veselkov, Robert Goldin, Paris Tekkis, Ara Darzi, Jeremy Nicholson, James Kinross, Zoltan Takats
BACKGROUND: This pilot study assessed the diagnostic accuracy of rapid evaporative ionization mass spectrometry (REIMS) in colorectal cancer (CRC) and colonic adenomas. METHODS: Patients undergoing elective surgical resection for CRC were recruited at St. Mary's Hospital London and The Royal Marsden Hospital, UK. Ex vivo analysis was performed using a standard electrosurgery handpiece with aspiration of the electrosurgical aerosol to a Xevo G2-S iKnife QTof mass spectrometer (Waters Corporation)...
August 8, 2016: Surgical Endoscopy
J Andrew Livingston, Kenneth R Hess, Aung Naing, David S Hong, Shreyaskumar Patel, Robert S Benjamin, Joseph A Ludwig, Anthony Conley, Cynthia E Herzog, Pete Anderson, Funda Meric-Bernstam, Razelle Kurzrock, Vivek Subbiah
BACKGROUND: We sought to validate the Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems for the selection of bone sarcoma patients for phase I clinical trials and to identify additional risk factors related to survival. PATIENTS AND METHODS: We retrospectively reviewed the baseline characteristics and outcomes of 92 bone sarcoma patients who were referred to MDACC's Phase I Clinical Trials Program. RESULTS: Ninety-two patients with Ewing sarcoma (N = 47), osteosarcoma (N = 22), chondrosarcoma (N = 16), and other tumors (N = 7) were evaluated; 78 were enrolled in at least 1 of 43 different phase I trials...
July 28, 2016: Oncotarget
Svetlana Balyasnikova, James Read, Diana Tait, Andrew Wotherspoon, Ian Swift, David Cunningham, Paris Tekkis, Gina Brown
AIM: The study aimed to establish the oncological outcome of patients who opted for close surveillance with or without adjuvant chemoradiotherapy (CRT) rather than radical surgery after local excision (LE) of early rectal cancer (ERC) METHOD: The Royal Marsden Hospital Rectal Cancer database was used to identify rectal cancer patients treated by primary LE from 2006-2015. All patients were entered in an intensive surveillance programme. RESULTS: Twenty eight of 34 analysed patients had a high or very high risk of residual disease predicted by adverse histopathological features for which the recommendation had been radical surgery...
July 30, 2016: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
Laurent Dercle, Samy Ammari, Stéphane Champiat, Christophe Massard, Charles Ferté, Lokmane Taihi, Romain-David Seban, Sandrine Aspeslagh, Linda Mahjoubi, Nyam Kamsu-Kom, Caroline Robert, Aurélien Marabelle, Martin Schlumberger, Jean-Charles Soria, Sophie Postel-Vinay
BACKGROUND: Drugs targeting programmed death receptor-1 (PD-1) and its ligand PD-L1 have shown activity in multiple malignancies. Considering their novel mechanism of action, whether traditional prognostic scores also apply to patients treated with these drugs is unknown. We investigated whether a baseline 3-point (pt) computed tomography (CT) scan (PS3-CT) score and a 7-pt prognostic (PS7) score allowed identifying long-term survivors on anti-PD-1/-L1 therapy. MATERIALS AND METHODS: We reviewed 251 consecutive patients enrolled in phase I trials evaluating anti-PD-1/-L1 agents between 26th December 2011 and 7th September 2015...
September 2016: European Journal of Cancer
Priya Sriskandarajah, Charlotte Pawlyn, Kabir Mohammed, Claire E Dearden, Faith E Davies, Gareth J Morgan, Kevin D Boyd, Martin F Kaiser
No abstract text is available yet for this article.
July 20, 2016: Leukemia & Lymphoma
Adam R Brentnall, Jack Cuzick, Helen Byers, Corrinne Segal, Caroline Reuter, Simone Detre, Ivana Sestak, Anthony Howell, Trevor J Powles, William G Newman, Mitchell Dowsett
A case-control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict which women will derive most anti-cancer benefit from selective oestrogen receptor modulator (SERM) therapy. In this article, we further examine this question using blood samples from two randomised tamoxifen prevention trials: the International Breast Cancer Intervention Study I (IBIS-I) and the Royal Marsden trial (Marsden)...
August 2016: Breast Cancer Research and Treatment
Maria Komisarenko, Narhari Timilshina, Patrick O Richard, Shabbir M H Alibhai, Robert Hamilton, Girish Kulkarni, Alexandre Zlotta, Neil Fleshner, Antonio Finelli
PURPOSE: We reviewed various existing active surveillance criteria and determined the competing trade-offs of the stricter vs more inclusive active surveillance criteria. MATERIALS AND METHODS: Men enrolled in an active surveillance program at Princess Margaret Cancer Centre between 1998 and 2014 were identified through a prospectively maintained database. All patients were assessed for entry eligibility into the Prostate Cancer Research International: Active Surveillance, Johns Hopkins, University of Miami, University of California San Francisco, Memorial Sloan Kettering Cancer Center, University of Toronto-Sunnybrook and Royal Marsden protocols...
June 24, 2016: Journal of Urology
Natalie Percival, Angela George, Jennifer Gyertson, Monica Hamill, Andreia Fernandes, Emily Davies, Nazneen Rahman, Susana Banerjee
PURPOSE: The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as the mainstreaming oncogenetic pathway, involving oncology health professionals are being used. The authors report on the establishment of the extended role of the clinical nurse specialist in consenting women for BRCA testing in routine gynaecology-oncology clinics using the mainstreaming model...
June 23, 2016: British Journal of Nursing: BJN
(no author information available yet)
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust have launched the United Kingdom's first pediatric genetic testing program. The groups aim to bring the same precision medicine options to children that are currently available to many adults with cancer.
July 2016: Cancer Discovery
I De Francesco, K Thomas, L Wedlake, D Tait
AIMS: To assess the potential impact on long-term consequences of treatment (intensity-modulated radiotherapy with concomitant chemotherapy) in patients diagnosed with anal cancer. MATERIALS AND METHODS: We identified 43 eligible patients treated with concomitant chemoradiotherapy (pelvic intensity-modulated radiotherapy) at the Royal Marsden Hospital between 2010 and 2013. We determined late genitalia and bowel side-effects using specific questionnaires [Pelvic Symptom Questionnaire, Vaizey Incontinence Questionnaire, Inflammatory Bowel Disease Questionnaire (IBDQ) and IBDQ-B]...
September 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
Khurum H Khan, Mabel Wong, Karim Rihawi, Shankar Bodla, Daniel Morganstein, Udai Banerji, Lulama R Molife
BACKGROUND: Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in human cancer growth and progression. Agents targeting this pathway are associated with hyperglycemia due to interaction with the insulin-glucose regulatory axis. Identifying the predictive factors for hyperglycemia in patients treated with these agents may help direct future management. MATERIALS AND METHODS: Clinical characteristics and outcomes of patients treated consecutively with PI3K, AKT, or mTOR inhibitors in the Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, between 2007 and 2012 were recorded...
July 2016: Oncologist
Emmanuelle Kempf, Nathalie Lemoine, Gabrielle Tergemina-Clain, Anthony Turpin, Sophie Postel-Vinay, Emilie Lanoy, Jean-Charles Soria, Christophe Massard, Antoine Hollebecque
INTRODUCTION: Enrolling cancer patients in phase I clinical trials (P1s) requires that they fulfill specific criteria. Between the time they sign the consent form and the 1st administration of the experimental drug, some patients may be excluded and considered as screen failures (SFs). Our objective was to assess SF patients profiles and the reasons and risk factors for SFs. MATERIALS AND METHODS: All patients included in P1s at Gustave Roussy from 2008 to 2013 were reviewed retrospectively...
2016: PloS One
A Khan, J Zhang, V Sollazzo, K Mohammed, G Gui
BACKGROUND: Comprehensive studies of somatosensory change following breast reconstruction are limited. We investigated altered sensation quantitatively and qualitatively in patients undergoing mastectomies for cancer treatment and unaffected individuals who had risk-reducing mastectomies (RRM) for cancer predisposing genes. METHODS: Women attending breast clinic review at Royal Marsden Hospital, London were invited to participate. Sensory testing was performed a minimum of 1 year after surgery...
July 2016: European Journal of Surgical Oncology
Lih-Ming Wong, Vincent Tang, Justin Peters, Anthony Costello, Niall Corcoran
OBJECTIVE: To examine the feasibility of active surveillance for low volume Gleason sum (GS) 3 + 4 disease compared to GS 3 + 3 disease. PATIENTS AND METHODS: Retrospective review of 929 patients, with biopsy proven GS 3 + 3 and 3 + 4 PCa, undergoing upfront radical prostatectomy (RP) was performed. Suitability for AS was adapted from protocols by Royal Marsden Hospital, University of Toronto, and PRIAS by allowing Gleason 3 + 4 disease. The outcomes assessed were adverse pathology at RP (upgrading ≥GS 4 + 3 and/or upstaging ≥pT3) and biochemical recurrence (BCR) after RP...
April 2016: BJU International
Dario Callegaro, Rosalba Miceli, Sylvie Bonvalot, Peter Ferguson, Dirk C Strauss, Antonin Levy, Anthony Griffin, Andrew J Hayes, Silvia Stacchiotti, Cecile Le Pechoux, Myles J Smith, Marco Fiore, Angelo P Dei Tos, Henry G Smith, Luigi Mariani, Jay S Wunder, Raphael E Pollock, Paolo G Casali, Alessandro Gronchi
BACKGROUND: The current American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system does not have sufficient details to encompass the variety of soft-tissue sarcomas, and available prognostic methods need refinement. We aimed to develop and externally validate two prediction nomograms for overall survival and distant metastases in patients with soft-tissue sarcoma in their extremities. METHODS: Consecutive patients who had had an operation at the Istituto Nazionale Tumori (Milan, Italy), from Jan 1, 1994, to Dec 31, 2013, formed the development cohort...
May 2016: Lancet Oncology
Roslyn Bonar, Emmanuel J Favaloro, Soma Mohammed, Monica Ahuja, Leonardo Pasalic, John Sioufi, Katherine Marsden
The direct oral anticoagulants (DOACs), now including dabigatran, apixaban and rivaroxaban, have given clinicians alternative options to low molecular weight heparins (LMWHs) and vitamin K antagonist therapy, including warfarin, for the treatment of atrial fibrillation and treatment and prevention of venous thromboembolic (VTE) disease. DOACs have been successfully marketed as not requiring monitoring; however, there will be situations where clinicians will request laboratory testing, including emergency department admissions for haemorrhage or thrombosis, or emergency surgical interventions...
January 2016: Pathology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"